Clinical role of d-sotalol and d,l-sotalol in supraventricular arrhythmias, including pre-excitation
Identifieur interne : 001B11 ( Istex/Corpus ); précédent : 001B10; suivant : 001B12Clinical role of d-sotalol and d,l-sotalol in supraventricular arrhythmias, including pre-excitation
Auteurs : C. Daubert ; P. Mabo ; D. Gras ; C. LeclercoSource :
- European Heart Journal [ 0195-668X ] ; 1993-11.
Abstract
Numerous trials performed over the last 20 years, although uncontrolled, have shown the racemic d,l-sotalol is effective for the acute conversion and for long-term prevention of recurrences of supraventricular tachyarrhythmias. Sotalol appeared to be moderately effective in atrial fibrillation or atrial flutter, having somewhat greater efficacy in the case of atrioventricular (AV) nodal re-entrant tachycardia due to Wolff-Parkinson-White syndrome or concealed accessory pathway. These effects may stem from the combined class II and class III electrophysiologic properties of this drug. However, studies comparing d,l-sotalol to pure beta blockers in different ‘models’, especially postsurgical arrhythmias and Wolff-Parkinson-White syndrome, have suggested that the observed clinical benefit may be related to d,l-sotalol's class III properties. Thus, d-sotalol may be efficacious in these indications. Its precise efficacy should be defined in controlled clinical trials.
Url:
DOI: 10.1093/eurheartj/14.suppl_H.67
Links to Exploration step
ISTEX:E2AE7F383C55138A3F0C592F9BEBD5922363BFDBLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Clinical role of d-sotalol and d,l-sotalol in supraventricular arrhythmias, including pre-excitation</title><author><name sortKey="Daubert, C" sort="Daubert, C" uniqKey="Daubert C" first="C." last="Daubert">C. Daubert</name><affiliation><mods:affiliation>Service de Cardiologie, Hotel Dieu/Centre Hospitalier Regional et Universitaire, 35033 Rennes Cedex, France</mods:affiliation></affiliation></author><author><name sortKey="Mabo, P" sort="Mabo, P" uniqKey="Mabo P" first="P." last="Mabo">P. Mabo</name><affiliation><mods:affiliation>Service de Cardiologie, Hotel Dieu/Centre Hospitalier Regional et Universitaire, 35033 Rennes Cedex, France</mods:affiliation></affiliation></author><author><name sortKey="Gras, D" sort="Gras, D" uniqKey="Gras D" first="D." last="Gras">D. Gras</name><affiliation><mods:affiliation>Service de Cardiologie, Hotel Dieu/Centre Hospitalier Regional et Universitaire, 35033 Rennes Cedex, France</mods:affiliation></affiliation></author><author><name sortKey="Leclerco, C" sort="Leclerco, C" uniqKey="Leclerco C" first="C." last="Leclerco">C. Leclerco</name><affiliation><mods:affiliation>Service de Cardiologie, Hotel Dieu/Centre Hospitalier Regional et Universitaire, 35033 Rennes Cedex, France</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E2AE7F383C55138A3F0C592F9BEBD5922363BFDB</idno><date when="1993" year="1993">1993</date><idno type="doi">10.1093/eurheartj/14.suppl_H.67</idno><idno type="url">https://api.istex.fr/document/E2AE7F383C55138A3F0C592F9BEBD5922363BFDB/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001B11</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001B11</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Clinical role of d-sotalol and d,l-sotalol in supraventricular arrhythmias, including pre-excitation</title><author><name sortKey="Daubert, C" sort="Daubert, C" uniqKey="Daubert C" first="C." last="Daubert">C. Daubert</name><affiliation><mods:affiliation>Service de Cardiologie, Hotel Dieu/Centre Hospitalier Regional et Universitaire, 35033 Rennes Cedex, France</mods:affiliation></affiliation></author><author><name sortKey="Mabo, P" sort="Mabo, P" uniqKey="Mabo P" first="P." last="Mabo">P. Mabo</name><affiliation><mods:affiliation>Service de Cardiologie, Hotel Dieu/Centre Hospitalier Regional et Universitaire, 35033 Rennes Cedex, France</mods:affiliation></affiliation></author><author><name sortKey="Gras, D" sort="Gras, D" uniqKey="Gras D" first="D." last="Gras">D. Gras</name><affiliation><mods:affiliation>Service de Cardiologie, Hotel Dieu/Centre Hospitalier Regional et Universitaire, 35033 Rennes Cedex, France</mods:affiliation></affiliation></author><author><name sortKey="Leclerco, C" sort="Leclerco, C" uniqKey="Leclerco C" first="C." last="Leclerco">C. Leclerco</name><affiliation><mods:affiliation>Service de Cardiologie, Hotel Dieu/Centre Hospitalier Regional et Universitaire, 35033 Rennes Cedex, France</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">European Heart Journal</title><idno type="ISSN">0195-668X</idno><idno type="eISSN">1522-9645</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="1993-11">1993-11</date><biblScope unit="volume">14</biblScope><biblScope unit="supplement">suppl_H</biblScope><biblScope unit="page" from="67">67</biblScope><biblScope unit="page" to="73">73</biblScope></imprint><idno type="ISSN">0195-668X</idno></series><idno type="istex">E2AE7F383C55138A3F0C592F9BEBD5922363BFDB</idno><idno type="DOI">10.1093/eurheartj/14.suppl_H.67</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0195-668X</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">Numerous trials performed over the last 20 years, although uncontrolled, have shown the racemic d,l-sotalol is effective for the acute conversion and for long-term prevention of recurrences of supraventricular tachyarrhythmias. Sotalol appeared to be moderately effective in atrial fibrillation or atrial flutter, having somewhat greater efficacy in the case of atrioventricular (AV) nodal re-entrant tachycardia due to Wolff-Parkinson-White syndrome or concealed accessory pathway. These effects may stem from the combined class II and class III electrophysiologic properties of this drug. However, studies comparing d,l-sotalol to pure beta blockers in different ‘models’, especially postsurgical arrhythmias and Wolff-Parkinson-White syndrome, have suggested that the observed clinical benefit may be related to d,l-sotalol's class III properties. Thus, d-sotalol may be efficacious in these indications. Its precise efficacy should be defined in controlled clinical trials.</div></front></TEI><istex><corpusName>oup</corpusName><author><json:item><name>C. Daubert</name><affiliations><json:string>Service de Cardiologie, Hotel Dieu/Centre Hospitalier Regional et Universitaire, 35033 Rennes Cedex, France</json:string></affiliations></json:item><json:item><name>P. Mabo</name><affiliations><json:string>Service de Cardiologie, Hotel Dieu/Centre Hospitalier Regional et Universitaire, 35033 Rennes Cedex, France</json:string></affiliations></json:item><json:item><name>D. Gras</name><affiliations><json:string>Service de Cardiologie, Hotel Dieu/Centre Hospitalier Regional et Universitaire, 35033 Rennes Cedex, France</json:string></affiliations></json:item><json:item><name>C. Leclerco</name><affiliations><json:string>Service de Cardiologie, Hotel Dieu/Centre Hospitalier Regional et Universitaire, 35033 Rennes Cedex, France</json:string></affiliations></json:item></author><subject><json:item><value>Articles</value></json:item><json:item><value>d-Sotalol</value></json:item><json:item><value>d,l-sotalol</value></json:item><json:item><value>supraventricular arrhythmia</value></json:item><json:item><value>atrial fibrillation</value></json:item><json:item><value>atrial flutter</value></json:item><json:item><value>Wolff-Parkinson-White syndrome</value></json:item></subject><language><json:string>unknown</json:string></language><originalGenre><json:string>research-article</json:string></originalGenre><abstract>Numerous trials performed over the last 20 years, although uncontrolled, have shown the racemic d,l-sotalol is effective for the acute conversion and for long-term prevention of recurrences of supraventricular tachyarrhythmias. Sotalol appeared to be moderately effective in atrial fibrillation or atrial flutter, having somewhat greater efficacy in the case of atrioventricular (AV) nodal re-entrant tachycardia due to Wolff-Parkinson-White syndrome or concealed accessory pathway. These effects may stem from the combined class II and class III electrophysiologic properties of this drug. However, studies comparing d,l-sotalol to pure beta blockers in different ‘models’, especially postsurgical arrhythmias and Wolff-Parkinson-White syndrome, have suggested that the observed clinical benefit may be related to d,l-sotalol's class III properties. Thus, d-sotalol may be efficacious in these indications. Its precise efficacy should be defined in controlled clinical trials.</abstract><qualityIndicators><score>7.762</score><pdfVersion>1.5</pdfVersion><pdfPageSize>595.44 x 841.68 pts</pdfPageSize><refBibsNative>false</refBibsNative><keywordCount>7</keywordCount><abstractCharCount>977</abstractCharCount><pdfWordCount>4202</pdfWordCount><pdfCharCount>28104</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>130</abstractWordCount></qualityIndicators><title>Clinical role of d-sotalol and d,l-sotalol in supraventricular arrhythmias, including pre-excitation</title><refBibs><json:item><author><json:item><name>Bn Singh</name></json:item><json:item><name> Vaughan</name></json:item><json:item><name>Em William</name></json:item></author><host><volume>39</volume><pages><last>89</last><first>675</first></pages><author></author><title>Br J Pharmacol</title><publicationDate>1970</publicationDate></host><title>A third class of antiarrhythmic action: Effects on atrial and ventricular potentials, and other pharmacological actions on cardiac muscle of MJ 1999 and AN 3474</title><publicationDate>1970</publicationDate></json:item><json:item><author><json:item><name>Hc Strauss</name></json:item><json:item><name>Jt Bigger</name></json:item><json:item><name>Bf Hoffman</name></json:item></author><host><volume>26</volume><pages><last>70</last><first>661</first></pages><author></author><title>Circ Res</title><publicationDate>1970</publicationDate></host><title>Electrophysiologic and beta-receptor blocking effects of MJ 1999 on dog and rabbit cardiac tissue</title><publicationDate>1970</publicationDate></json:item><json:item><author><json:item><name>F Fogelman</name></json:item><json:item><name>Sl Lightman</name></json:item><json:item><name>Rw Sillet</name></json:item><json:item><name>Mw Mcnicoll</name></json:item></author><host><volume>5</volume><pages><last>6</last><first>72</first></pages><author></author><title>Eur J Clin Pharmacol</title><publicationDate>1972</publicationDate></host><title>The treatment of cardiac arrhythmias with sotalol</title><publicationDate>1972</publicationDate></json:item><json:item><author><json:item><name>R Prakash</name></json:item><json:item><name>Ww Parmley</name></json:item><json:item><name>Nh Allen</name></json:item><json:item><name>Jm Matloff</name></json:item></author><host><volume>29</volume><pages><last>400</last><first>397</first></pages><author></author><title>Am J Cardiol</title><publicationDate>1971</publicationDate></host><title>Effect of sotalol on clinical arrhythmias</title><publicationDate>1971</publicationDate></json:item><json:item><author><json:item><name>S Levy</name></json:item><json:item><name>Jc Rovini</name></json:item><json:item><name>M Metge</name></json:item></author><host><volume>79</volume><pages><last>5</last><first>1781</first></pages><author></author><title>Arch Mai Coeur</title><publicationDate>1986</publicationDate></host><title>Le sotalol intraveineux dans le traitement aigu des tachycardies supraventriculaires</title><publicationDate>1986</publicationDate></json:item><json:item><author><json:item><name>Kk Teo</name></json:item><json:item><name>M Harte</name></json:item><json:item><name>Jh Morgan</name></json:item></author><host><volume>87</volume><pages><last>8</last><first>113</first></pages><author></author><title>Chest</title><publicationDate>1985</publicationDate></host><title>Sotalol infusion in the treatment of supraventricular tachyarrhythmias</title><publicationDate>1985</publicationDate></json:item><json:item><author><json:item><name>K Okumura</name></json:item><json:item><name>A Scalabrini</name></json:item><json:item><name>Al Waldo</name></json:item></author><host><volume>7</volume><pages><first>250</first></pages><author></author><title>JACC</title><publicationDate>1986</publicationDate></host><title>Effects of d-anc 1-sotalol on atrial electrophysiology and atrial flutter induced in conscious dogs with sterile pericarditis</title><publicationDate>1986</publicationDate></json:item><json:item><author><json:item><name>Gk Feld</name></json:item><json:item><name>N Venkatesh</name></json:item><json:item><name>Bn Singh</name></json:item></author><host><volume>74</volume><pages><last>204</last><first>197</first></pages><author></author><title>Circulation</title><publicationDate>1986</publicationDate></host><title>Pharmacological conversion and suppression of experimental canine atrial flutter: Differing effects of d-sotalol, quinidine and lidocaine and significance of changes in refractoriness and conduction</title><publicationDate>1986</publicationDate></json:item><json:item><author><json:item><name>Tj Campbell</name></json:item><json:item><name>Tp Gavaghan</name></json:item><json:item><name>Jj Morgan</name></json:item></author><host><volume>54</volume><pages><last>90</last><first>86</first></pages><author></author><title>Br Heart J</title><publicationDate>1985</publicationDate></host><title>Intravenous sotalol for the treatment of atrial fibrillation and flutter after cardiopulmonary bypass</title><publicationDate>1985</publicationDate></json:item><json:item><author><json:item><name>Sn Singh</name></json:item><json:item><name>Rk Saini</name></json:item><json:item><name>Jd Dimarco</name></json:item><json:item><name>Klueger,J Gold</name></json:item><json:item><name>R </name></json:item></author><host><volume>15</volume><pages><first>27</first></pages><author></author><title>J Am Coll Cardiol</title><publicationDate>1990</publicationDate></host><title>Efficacy and safety of sotalol in digitalized patients with chronic AF</title><publicationDate>1990</publicationDate></json:item><json:item><author><json:item><name>M Beagan</name></json:item></author><host><author></author><title>Bristol-Myers Squibb Final Study Report 29305</title><publicationDate>1990-07-18</publicationDate></host><title>Multiple comparative study of the efficacy and safety of sotalol in the prophylactic treatment of patients with paroxysmal supraventricular tachycardias</title><publicationDate>1990-07-18</publicationDate></json:item><json:item><author><json:item><name>Aj Camm</name></json:item><json:item><name>V Paul</name></json:item></author><host><volume>65</volume><pages><last>73</last><first>67</first></pages><author></author><title>Am J Cardiol</title><publicationDate>1990</publicationDate></host><title>Sotalol for paroxysmal supraventricular tachycardias</title><publicationDate>1990</publicationDate></json:item><json:item><host><author><json:item><name> Bristol-Myers</name></json:item></author><title>Squibb ongoing trial (Study CV 101-014) Preliminary results (with permission from Bristol-Myers Squibb)</title></host></json:item><json:item><author><json:item><name>D Roy</name></json:item><json:item><name>X Muller</name></json:item><json:item><name>M Dethy</name></json:item></author><host><volume>80</volume><pages><first>633</first></pages><author></author><title>Circulation</title><publicationDate>1989</publicationDate></host><title>Is sotalol a better drug than digoxin for maintaining normal sinus rhythm after cardioversion of AF</title><publicationDate>1989</publicationDate></json:item><json:item><author><json:item><name>S Juul-Moller</name></json:item><json:item><name>N Edvardsson</name></json:item><json:item><name>N Rehnqvist-Ahlberg</name></json:item></author><host><volume>82</volume><pages><last>9</last><first>1932</first></pages><author></author><title>Circulation</title><publicationDate>1990</publicationDate></host><title>Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation</title><publicationDate>1990</publicationDate></json:item><json:item><author><json:item><name>Van Gelder</name></json:item><json:item><name>Ci Crijns</name></json:item><json:item><name>Hs </name></json:item></author><host><volume>80</volume><pages><first>633</first></pages><issue>Abstr</issue><author></author><title>Circulation</title><publicationDate>1989</publicationDate></host><title>Serial antiarrhythmic drug treatment for chronic atrial fibrillation and atrial flutter</title><publicationDate>1989</publicationDate></json:item><json:item><author><json:item><name>Em Antman</name></json:item><json:item><name>Ad Bearmer</name></json:item><json:item><name>C Cantillon</name></json:item></author><host><volume>15</volume><pages><last>707</last><first>608</first></pages><author></author><title>J Am Coll Cardiol</title><publicationDate>1990</publicationDate></host><title>Therapy of refractory symptomatic atrial fibrillation and atrial flutter: A staged care approach with new antiarrhythmic drugs</title><publicationDate>1990</publicationDate></json:item><json:item><author><json:item><name>Ja Thomis</name></json:item></author><host><volume>25326</volume><author></author><title>Bristol-Myers Squibb Final Study Report</title><publicationDate>1988-10-14</publicationDate></host><title>Acute effects of sotalol in paroxysmal supraventricular tachycardia: A double-blind, placebo-controlled, multicenter study</title><publicationDate>1988-10-14</publicationDate></json:item><json:item><author><json:item><name>A Waleffe</name></json:item><json:item><name>K Nzayinambaho</name></json:item><json:item><name>Lm Rodriguez</name></json:item><json:item><name>A Dehareng</name></json:item><json:item><name>He Kulbertus</name></json:item></author><host><volume>10</volume><pages><last>9</last><first>1084</first></pages><author></author><title>Eur Heart J</title><publicationDate>1989</publicationDate></host><title>Mechanism of termination of supraventricular tachycardias by intravenous class III antiarrhythmic agents. A comparison of amiodarone and sotalol</title><publicationDate>1989</publicationDate></json:item><json:item><author><json:item><name>L Jordaens</name></json:item><json:item><name>Gorgels,A Stroobandt</name></json:item><json:item><name>R Temmerman</name></json:item><json:item><name>J </name></json:item></author><host><volume>68</volume><pages><last>40</last><first>35</first></pages><author></author><title>Am J Cardiol</title><publicationDate>1991</publicationDate></host><title>Efficacy and safety of intravenous sotalol for termination of paroxysmal supraventricular tachycardia</title><publicationDate>1991</publicationDate></json:item><json:item><author><json:item><name>I Rizos</name></json:item><json:item><name>Senges,J Jauerning</name></json:item><json:item><name>R </name></json:item></author><host><volume>53</volume><pages><last>7</last><first>22</first></pages><author></author><title>Am J Cardiol</title><publicationDate>1984</publicationDate></host><title>Differential effects of sotalol and metoprolol on induction of paroxysmal supraventricular tachycardia</title><publicationDate>1984</publicationDate></json:item><json:item><author><json:item><name>Hv Huikuri</name></json:item><json:item><name>Mj Koistinen</name></json:item><json:item><name>Jt Takkunen</name></json:item></author><host><volume>12</volume><pages><first>223</first></pages><author></author><title>Eur Heart J</title><publicationDate>1991</publicationDate></host><title>Effiacy of intravenous sotalol for suppressing inducibility of supraventricular tachycardias at rest and during exercise</title><publicationDate>1991</publicationDate></json:item><json:item><author><json:item><name>M Borggrefe</name></json:item><json:item><name>G Breithardt</name></json:item></author><host><volume>74</volume><pages><last>11</last><first>506</first></pages><author></author><title>Z Kardiol</title><publicationDate>1985</publicationDate></host><title>Electrophysiologic effect of sotalol in supraventricular tachycardias</title><publicationDate>1985</publicationDate></json:item><json:item><author><json:item><name>M Manz</name></json:item><json:item><name>Aj Kuhl</name></json:item><json:item><name>B Luderitz</name></json:item></author><host><volume>74</volume><pages><last>5</last><first>560</first></pages><author></author><title>Z Kardiol</title><publicationDate>1985</publicationDate></host><title>Sotalol in supraventricular tachycardia Electrophysiologic measurements in Wolff- Parkinson-White syndrome and AV nodal re-entry tachycardia</title><publicationDate>1985</publicationDate></json:item><json:item><author><json:item><name>Kp Kunze</name></json:item><json:item><name>M Schulter</name></json:item><json:item><name>Kh Kuck</name></json:item></author><host><volume>76</volume><pages><last>7</last><first>1050</first></pages><author></author><title>Circulation</title><publicationDate>1987</publicationDate></host><title>Sotalol in patients with Wolff-Parkinson-White syndrome</title><publicationDate>1987</publicationDate></json:item><json:item><author><json:item><name>P Touboul</name></json:item><json:item><name>G Atallah</name></json:item><json:item><name>G Kirkorian</name></json:item><json:item><name>P Lavaud</name></json:item><json:item><name>M Matthieu</name></json:item><json:item><name>A Dellinger</name></json:item></author><host><volume>114</volume><pages><last>50</last><first>545</first></pages><author></author><title>Am Heart J</title><publicationDate>1987</publicationDate></host><title>Effects of intravenous sotalol in patients with atrioventricular accessory pathway</title><publicationDate>1987</publicationDate></json:item><json:item><author><json:item><name>Lb Mitchell</name></json:item><json:item><name>G Wyse</name></json:item><json:item><name>Hj Duff</name></json:item></author><host><volume>76</volume><pages><last>8</last><first>810</first></pages><author></author><title>Circulation</title><publicationDate>1987</publicationDate></host><title>Electropharmacology of sotalol in patients with Wolff-Parkinson-White syndrome</title><publicationDate>1987</publicationDate></json:item><json:item><author><json:item><name>Dm Cassidy</name></json:item><json:item><name>A Arenal</name></json:item><json:item><name>D Roy</name></json:item></author><host><volume>9</volume><pages><first>49</first></pages><author></author><title>J Am Coll Cardiol</title><publicationDate>1987</publicationDate></host><title>Oral sotalol: electrophysiological effects and long-term efficacy in patients with recurrent supraventricular tachycardia</title><publicationDate>1987</publicationDate></json:item><json:item><author><json:item><name>Aw Nathan</name></json:item><json:item><name>Kj Hellestrand</name></json:item><json:item><name>Rs Bexton</name></json:item><json:item><name>Ra Spurell</name></json:item><json:item><name>Aj Camm</name></json:item></author><host><volume>47</volume><pages><last>20</last><first>515</first></pages><author></author><title>Br Heart J</title><publicationDate>1982</publicationDate></host><title>Electrophysiological effects of sotalol: Just another beta-blocker?</title><publicationDate>1982</publicationDate></json:item><json:item><author><json:item><name>Jj Blanc</name></json:item><json:item><name>J Boschat</name></json:item><json:item><name>Jp Ollivier</name></json:item><json:item><name>Ph Penther</name></json:item></author><host><volume>78</volume><pages><last>102</last><first>1097</first></pages><author></author><title>Arch Mai Coeur</title><publicationDate>1985</publicationDate></host><title>Effets du sotalol per os sur la conduction des voies accessories auriculo-ventricularies</title><publicationDate>1985</publicationDate></json:item><json:item><author><json:item><name>J Janssen</name></json:item><json:item><name>L Loomans</name></json:item><json:item><name>J Haring</name></json:item></author><host><volume>36</volume><pages><last>4</last><first>601</first></pages><author></author><title>Angiology</title><publicationDate>1985</publicationDate></host><title>Prevention and treatment of supraventricular tachycardia shortly after coronary bypass grafting: A randomized open trial</title><publicationDate>1985</publicationDate></json:item><json:item><author><json:item><name>Mj Suttrop</name></json:item><json:item><name>Jh Kingma</name></json:item><json:item><name>Tjon,Joe Gin</name></json:item><json:item><name>Rm </name></json:item></author><host><volume>100</volume><pages><last>6</last><first>921</first></pages><author></author><title>J Thorac Cardiovasc Surg</title><publicationDate>1990</publicationDate></host><title>Efficacy and safety of low-and high-dose sotalol versus propranolol in the prevention of supraventricular tachyarrhythmias early after coronary bypass operations</title><publicationDate>1990</publicationDate></json:item><json:item><author><json:item><name>P Mabo</name></json:item><json:item><name>C Daubert</name></json:item><json:item><name>P Druelles</name></json:item><json:item><name>Le Breton</name></json:item><json:item><name>H Paillard</name></json:item><json:item><name>F Vrancea</name></json:item><json:item><name>F </name></json:item></author><host><volume>80</volume><pages><first>535</first></pages><author></author><title>Circulation</title><publicationDate>1989</publicationDate></host><title>Oral sotalol versus oral propranolol in Wolff-Parkinson-White syndrome: Eleclrophysiologic study at rest and on exercise</title><publicationDate>1989</publicationDate></json:item><json:item><author><json:item><name>M Akhtar</name></json:item><json:item><name>I Niazi</name></json:item><json:item><name>Gv Naccarelli</name></json:item></author><host><volume>62</volume><pages><last>9</last><first>45</first></pages><author></author><title>Am J Cardiol</title><publicationDate>1988</publicationDate></host><title>Role of adrenergic stimulation by isoproterenol in reversal of effects of encainide in supraventricular tachycardia</title><publicationDate>1988</publicationDate></json:item><json:item><author><json:item><name>As Manolis</name></json:item><json:item><name>N Estes</name></json:item></author><host><volume>64</volume><pages><last>8</last><first>194</first></pages><author></author><title>Am J Cardiol</title><publicationDate>1989</publicationDate></host><title>Reversal of electrophysiologic effects of flecainide on the accessory pathway by isoproterenol in the Wolff-Parkinson-White syndrome</title><publicationDate>1989</publicationDate></json:item><json:item><author><json:item><name>F Morady</name></json:item><json:item><name>Wh Kou</name></json:item><json:item><name>Ah Kadish</name></json:item><json:item><name>Lk Toivonen</name></json:item><json:item><name>Ja Kushner</name></json:item><json:item><name>S Schmaltz</name></json:item></author><host><volume>79</volume><pages><last>90</last><first>783</first></pages><author></author><title>Circulation</title><publicationDate>1989</publicationDate></host><title>Epinephrine-induced reversal of verapamil's electrophysiologic and therapeutic effects in patients with paroxysmal supraventricular tachycardia</title><publicationDate>1989</publicationDate></json:item><json:item><author><json:item><name>Dl Sahar</name></json:item><json:item><name>Ja Reiffel</name></json:item><json:item><name>Jt Bigger</name></json:item><json:item><name>Squatrito,A Kidwell</name></json:item><json:item><name>Ga </name></json:item></author><host><volume>117</volume><pages><last>8</last><first>562</first></pages><author></author><title>Am Heart J</title><publicationDate>1989</publicationDate></host><title>Efficacy, safety, and tolerance of d-sotalol in patients with refractory supraventricular tachyarrhythmias</title><publicationDate>1989</publicationDate></json:item></refBibs><genre><json:string>research-article</json:string></genre><host><volume>14</volume><publisherId><json:string>eurheartj</json:string></publisherId><pages><last>73</last><first>67</first></pages><issn><json:string>0195-668X</json:string></issn><genre><json:string>journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1522-9645</json:string></eissn><title>European Heart Journal</title></host><categories><wos><json:string>science</json:string><json:string>cardiac & cardiovascular systems</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>cardiovascular system & hematology</json:string></scienceMetrix></categories><publicationDate>1993</publicationDate><copyrightDate>1993</copyrightDate><doi><json:string>10.1093/eurheartj/14.suppl_H.67</json:string></doi><id>E2AE7F383C55138A3F0C592F9BEBD5922363BFDB</id><score>0.32668257</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/E2AE7F383C55138A3F0C592F9BEBD5922363BFDB/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/E2AE7F383C55138A3F0C592F9BEBD5922363BFDB/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/E2AE7F383C55138A3F0C592F9BEBD5922363BFDB/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a">Clinical role of d-sotalol and d,l-sotalol in supraventricular arrhythmias, including pre-excitation</title><respStmt><resp>Références bibliographiques récupérées via GROBID</resp><name resp="ISTEX-API">ISTEX-API (INIST-CNRS)</name></respStmt></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Oxford University Press</publisher><availability><p>© 1993 The European Society of Cardiology</p></availability><date>1993</date></publicationStmt><notesStmt><note>Correspondence: Pr J. Claude Daubert, Service de Cardiologie, Hotel Dieu/Centre Hospitalier Regional et Universitaire, 35033 Rennes Cedex, France</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">Clinical role of d-sotalol and d,l-sotalol in supraventricular arrhythmias, including pre-excitation</title><author xml:id="author-1"><persName><forename type="first">C.</forename><surname>Daubert</surname></persName><affiliation>Service de Cardiologie, Hotel Dieu/Centre Hospitalier Regional et Universitaire, 35033 Rennes Cedex, France</affiliation></author><author xml:id="author-2"><persName><forename type="first">P.</forename><surname>Mabo</surname></persName><affiliation>Service de Cardiologie, Hotel Dieu/Centre Hospitalier Regional et Universitaire, 35033 Rennes Cedex, France</affiliation></author><author xml:id="author-3"><persName><forename type="first">D.</forename><surname>Gras</surname></persName><affiliation>Service de Cardiologie, Hotel Dieu/Centre Hospitalier Regional et Universitaire, 35033 Rennes Cedex, France</affiliation></author><author xml:id="author-4"><persName><forename type="first">C.</forename><surname>Leclerco</surname></persName><affiliation>Service de Cardiologie, Hotel Dieu/Centre Hospitalier Regional et Universitaire, 35033 Rennes Cedex, France</affiliation></author></analytic><monogr><title level="j">European Heart Journal</title><idno type="pISSN">0195-668X</idno><idno type="eISSN">1522-9645</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="1993-11"></date><biblScope unit="volume">14</biblScope><biblScope unit="supplement">suppl_H</biblScope><biblScope unit="page" from="67">67</biblScope><biblScope unit="page" to="73">73</biblScope></imprint></monogr><idno type="istex">E2AE7F383C55138A3F0C592F9BEBD5922363BFDB</idno><idno type="DOI">10.1093/eurheartj/14.suppl_H.67</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1993</date></creation><abstract><p>Numerous trials performed over the last 20 years, although uncontrolled, have shown the racemic d,l-sotalol is effective for the acute conversion and for long-term prevention of recurrences of supraventricular tachyarrhythmias. Sotalol appeared to be moderately effective in atrial fibrillation or atrial flutter, having somewhat greater efficacy in the case of atrioventricular (AV) nodal re-entrant tachycardia due to Wolff-Parkinson-White syndrome or concealed accessory pathway. These effects may stem from the combined class II and class III electrophysiologic properties of this drug. However, studies comparing d,l-sotalol to pure beta blockers in different ‘models’, especially postsurgical arrhythmias and Wolff-Parkinson-White syndrome, have suggested that the observed clinical benefit may be related to d,l-sotalol's class III properties. Thus, d-sotalol may be efficacious in these indications. Its precise efficacy should be defined in controlled clinical trials.</p></abstract><textClass><keywords scheme="keyword"><list><item><term>Articles</term></item></list></keywords></textClass><textClass><keywords scheme="keyword"><list><head>keywords</head><item><term>d-Sotalol</term></item><item><term>d,l-sotalol</term></item><item><term>supraventricular arrhythmia</term></item><item><term>atrial fibrillation</term></item><item><term>atrial flutter</term></item><item><term>Wolff-Parkinson-White syndrome</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1993-11">Published</change><change xml:id="refBibs-istex" who="#ISTEX-API" when="2016-12-22">References added</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/E2AE7F383C55138A3F0C592F9BEBD5922363BFDB/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus oup" wicri:toSee="no header"><istex:docType PUBLIC="-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" URI="journalpublishing.dtd" name="istex:docType"></istex:docType><istex:document><article article-type="research-article"><front><journal-meta><journal-id journal-id-type="hwp">ehj</journal-id><journal-id journal-id-type="archive">eurheartj</journal-id><journal-id journal-id-type="publisher-id">eurheartj</journal-id><journal-title>European Heart Journal</journal-title><issn pub-type="ppub">0195-668X</issn><issn pub-type="epub">1522-9645</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1093/eurheartj/14.suppl_H.67</article-id><article-categories><subj-group><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Clinical role of d-sotalol and d,l-sotalol in supraventricular arrhythmias, including pre-excitation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Daubert</surname><given-names>C.</given-names></name><xref ref-type="corresp" rid="cor1"></xref></contrib><contrib contrib-type="author"><name><surname>Mabo</surname><given-names>P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Gras</surname><given-names>D.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Leclerco</surname><given-names>C.</given-names></name></contrib><aff><institution>Service de Cardiologie, Hotel Dieu/Centre Hospitalier Regional et Universitaire</institution> <addr-line>35033 Rennes Cedex, France</addr-line></aff></contrib-group><author-notes><corresp id="cor1"><italic>Correspondence</italic>: Pr J. Claude Daubert, Service de Cardiologie, Hotel Dieu/Centre Hospitalier Regional et Universitaire, 35033 Rennes Cedex, France</corresp></author-notes><pub-date pub-type="ppub"><month>11</month><year>1993</year></pub-date><volume>14</volume><issue>suppl_H</issue><fpage>67</fpage><lpage>73</lpage><copyright-statement>© 1993 The European Society of Cardiology</copyright-statement><copyright-year>1993</copyright-year><abstract><p>Numerous trials performed over the last 20 years, although uncontrolled, have shown the racemic d,l-sotalol is effective for the acute conversion and for long-term prevention of recurrences of supraventricular tachyarrhythmias. Sotalol appeared to be moderately effective in atrial fibrillation or atrial flutter, having somewhat greater efficacy in the case of atrioventricular (AV) nodal re-entrant tachycardia due to Wolff-Parkinson-White syndrome or concealed accessory pathway. These effects may stem from the combined class II and class III electrophysiologic properties of this drug. However, studies comparing d,l-sotalol to pure beta blockers in different ‘models’, especially postsurgical arrhythmias and Wolff-Parkinson-White syndrome, have suggested that the observed clinical benefit may be related to d,l-sotalol's class III properties. Thus, d-sotalol may be efficacious in these indications. Its precise efficacy should be defined in controlled clinical trials.</p></abstract><kwd-group><kwd>d-Sotalol</kwd><kwd>d,l-sotalol</kwd><kwd>supraventricular arrhythmia</kwd><kwd>atrial fibrillation</kwd><kwd>atrial flutter</kwd><kwd>Wolff-Parkinson-White syndrome</kwd></kwd-group></article-meta></front></article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>Clinical role of d-sotalol and d,l-sotalol in supraventricular arrhythmias, including pre-excitation</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Clinical role of d-sotalol and d,l-sotalol in supraventricular arrhythmias, including pre-excitation</title></titleInfo><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Daubert</namePart><affiliation>Service de Cardiologie, Hotel Dieu/Centre Hospitalier Regional et Universitaire, 35033 Rennes Cedex, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P.</namePart><namePart type="family">Mabo</namePart><affiliation>Service de Cardiologie, Hotel Dieu/Centre Hospitalier Regional et Universitaire, 35033 Rennes Cedex, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D.</namePart><namePart type="family">Gras</namePart><affiliation>Service de Cardiologie, Hotel Dieu/Centre Hospitalier Regional et Universitaire, 35033 Rennes Cedex, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Leclerco</namePart><affiliation>Service de Cardiologie, Hotel Dieu/Centre Hospitalier Regional et Universitaire, 35033 Rennes Cedex, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="research-article"></genre><subject><topic>Articles</topic></subject><originInfo><publisher>Oxford University Press</publisher><dateIssued encoding="w3cdtf">1993-11</dateIssued><copyrightDate encoding="w3cdtf">1993</copyrightDate></originInfo><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract>Numerous trials performed over the last 20 years, although uncontrolled, have shown the racemic d,l-sotalol is effective for the acute conversion and for long-term prevention of recurrences of supraventricular tachyarrhythmias. Sotalol appeared to be moderately effective in atrial fibrillation or atrial flutter, having somewhat greater efficacy in the case of atrioventricular (AV) nodal re-entrant tachycardia due to Wolff-Parkinson-White syndrome or concealed accessory pathway. These effects may stem from the combined class II and class III electrophysiologic properties of this drug. However, studies comparing d,l-sotalol to pure beta blockers in different ‘models’, especially postsurgical arrhythmias and Wolff-Parkinson-White syndrome, have suggested that the observed clinical benefit may be related to d,l-sotalol's class III properties. Thus, d-sotalol may be efficacious in these indications. Its precise efficacy should be defined in controlled clinical trials.</abstract><note type="author-notes">Correspondence: Pr J. Claude Daubert, Service de Cardiologie, Hotel Dieu/Centre Hospitalier Regional et Universitaire, 35033 Rennes Cedex, France</note><subject><genre>keywords</genre><topic>d-Sotalol</topic><topic>d,l-sotalol</topic><topic>supraventricular arrhythmia</topic><topic>atrial fibrillation</topic><topic>atrial flutter</topic><topic>Wolff-Parkinson-White syndrome</topic></subject><relatedItem type="host"><titleInfo><title>European Heart Journal</title></titleInfo><genre type="journal">journal</genre><identifier type="ISSN">0195-668X</identifier><identifier type="eISSN">1522-9645</identifier><identifier type="PublisherID">eurheartj</identifier><identifier type="PublisherID-hwp">ehj</identifier><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><detail type="supplement"><number>suppl_H</number></detail><extent unit="pages"><start>67</start><end>73</end></extent></part></relatedItem><identifier type="istex">E2AE7F383C55138A3F0C592F9BEBD5922363BFDB</identifier><identifier type="DOI">10.1093/eurheartj/14.suppl_H.67</identifier><accessCondition type="use and reproduction" contentType="copyright">© 1993 The European Society of Cardiology</accessCondition><recordInfo><recordContentSource>OUP</recordContentSource></recordInfo></mods></metadata><annexes><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/E2AE7F383C55138A3F0C592F9BEBD5922363BFDB/annexes/pdf</uri></json:item></annexes><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B11 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001B11 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:E2AE7F383C55138A3F0C592F9BEBD5922363BFDB
|texte= Clinical role of d-sotalol and d,l-sotalol in supraventricular arrhythmias, including pre-excitation
}}
| This area was generated with Dilib version V0.6.29. |  |